In this video, health care analysts David Williamson and Max Macaluso discuss Vertex's recent tie up with two deep-pocketed members of big pharma. Although Vertex currently owns the standard of care for hepatitis C treatments, it isn't sitting on its laurels. Watch and find out what this new deal means for Vertex, its partners, and its competitors.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.